AIM: To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice. BACKGROUND: Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies. MATERIAL AND METHODS: We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated. RESULTS: 37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months. CONCLUSION: SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.
AIM: To evaluate clinical outcome in locally-advanced stage IV (M0) head and neck cancer patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in daily clinical practice. BACKGROUND: Despite SIB-IMRT has been reported as a feasible and effective advanced head and neck cancer treatment, there are few data about its concurrent use with systemic therapies. MATERIAL AND METHODS: We reviewed 41 staged IV (M0) head and neck cancer patients treated in two radiotherapy units in the city of Messina (Italy) during the last six years, using intensity modulated techniques-SIB. 22/41 patients had concomitant chemotherapy or cetuximab. Acute and late toxicities, objective response (OR) rate, local control (LC) and overall survival (OS) have been evaluated. RESULTS: 37/41 patients received the planned doses of radiotherapy, 2 patients died during the therapy. The major acute regional toxicities were skin reaction and mucositis. A case of mandibular osteoradionecrosis was recorded. At completion of treatment, OR was evaluated in 38 patients: 32/38 patients (84.2%) had complete (55.3%) and partial (28.9%) response. The 1- and 5-year LC rates were 73.4% and 69.73%, respectively. The 1-, 3-, and 5-year OS rates were 85.93%, 51.49% and 44.14%, respectively. No statistically significant differences in outcomes have been observed in patients treated with radiotherapy alone vs. irradiation concomitant to chemo/biotherapy. The median OS was 45 months. CONCLUSION: SIB-IMRT is safeand can be used with concomitant chemotherapy/biotherapy in real-life daily clinical practice. SIB-IMRT alone is a valid alternative in patients unfit for systemic therapies.
Authors: Aurora Mirabile; Gianmauro Numico; Elvio G Russi; Paolo Bossi; Fulvio Crippa; Almalina Bacigalupo; Vitaliana De Sanctis; Stefania Musso; Anna Merlotti; Maria Grazia Ghi; Marco C Merlano; Lisa Licitra; Francesco Moretto; Nerina Denaro; Orietta Caspiani; Michela Buglione; Stefano Pergolizzi; Antonio Cascio; Jacques Bernier; Judith Raber-Durlacher; Jan B Vermorken; Barbara Murphy; Marco V Ranieri; R Phillip Dellinger Journal: Crit Rev Oncol Hematol Date: 2015-03-19 Impact factor: 6.312
Authors: K Kian Ang; Jonathan Harris; Adam S Garden; Andy Trotti; Christopher U Jones; Luis Carrascosa; Jonathan D Cheng; Sharon S Spencer; Arlene Forastiere; Randal S Weber Journal: J Clin Oncol Date: 2005-05-01 Impact factor: 44.544
Authors: E B Butler; B S Teh; W H Grant; B M Uhl; R B Kuppersmith; J K Chiu; D T Donovan; S Y Woo Journal: Int J Radiat Oncol Biol Phys Date: 1999-08-01 Impact factor: 7.038
Authors: Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre Journal: N Engl J Med Date: 2007-10-25 Impact factor: 91.245
Authors: Vitaliana De Sanctis; Paolo Bossi; Giuseppe Sanguineti; Fabio Trippa; Daris Ferrari; Almalina Bacigalupo; Carla Ida Ripamonti; Michela Buglione; Stefano Pergolizzi; Johannes A Langendjik; Barbara Murphy; Judith Raber-Durlacher; Elvio G Russi; Rajesh V Lalla Journal: Crit Rev Oncol Hematol Date: 2016-02-01 Impact factor: 6.312
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Gianluca Ferini; Alberto Cacciola; Silvana Parisi; Sara Lillo; Laura Molino; Consuelo Tamburella; Valerio Davi; Ilenia Napoli; Angelo Platania; Nicola Settineri; Giuseppe Iati; Antonio Pontoriero; Stefano Pergolizzi; Anna Santacaterina Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155